Oleclumab
As of the edition of 20 October 2026, Oleclumab is an antibody: in active development; acts on NT5E.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 29, 3 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system; Urinary and reproductive; Hormones; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NT5E | 5'-nucleotidase | P21589 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 6 | 1 | 0 |
| Phase 2 | 21 | 5 | 12 | 3 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 29 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Lead sponsor of trials | 2015 to now |